Novo Nordisk A/S: Volatility continues unabated - InvestingChannel

Novo Nordisk A/S: Volatility continues unabated

Why has the stock fallen back?
Results for the quarter were in line with analysts’ expectations. Investors were initially delighted with the growth figures for Wegovy, the Group’s weight-loss drug, which did not disappoint, unlike Eli Lilly’s treatments in this indication. Sales of Wegovy soared by…
© MarketScreener.com 2024

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire